WO1996029002A1 - Methode de diagnostic de carences en hormone de croissance hypophysaire - Google Patents
Methode de diagnostic de carences en hormone de croissance hypophysaire Download PDFInfo
- Publication number
- WO1996029002A1 WO1996029002A1 PCT/US1996/003607 US9603607W WO9629002A1 WO 1996029002 A1 WO1996029002 A1 WO 1996029002A1 US 9603607 W US9603607 W US 9603607W WO 9629002 A1 WO9629002 A1 WO 9629002A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trp
- growth hormone
- ghrp
- phe
- ghrh
- Prior art date
Links
- 230000001817 pituitary effect Effects 0.000 title claims description 56
- 238000000034 method Methods 0.000 title claims description 35
- 206010056438 Growth hormone deficiency Diseases 0.000 title claims description 9
- 230000001419 dependent effect Effects 0.000 title claims description 6
- 102000018997 Growth Hormone Human genes 0.000 claims abstract description 345
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 345
- 239000000122 growth hormone Substances 0.000 claims abstract description 345
- 230000000580 secretagogue effect Effects 0.000 claims abstract description 59
- 230000007812 deficiency Effects 0.000 claims abstract description 41
- 210000004369 blood Anatomy 0.000 claims abstract description 36
- 239000008280 blood Substances 0.000 claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 230000003578 releasing effect Effects 0.000 claims abstract description 29
- 230000003248 secreting effect Effects 0.000 claims abstract description 23
- 230000007248 cellular mechanism Effects 0.000 claims abstract description 13
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 192
- 101710142969 Somatoliberin Proteins 0.000 claims description 192
- 230000004044 response Effects 0.000 claims description 91
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 230000002950 deficient Effects 0.000 claims description 20
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 16
- 230000037396 body weight Effects 0.000 claims description 15
- 206010062767 Hypophysitis Diseases 0.000 claims description 10
- 238000011260 co-administration Methods 0.000 claims description 10
- 230000007547 defect Effects 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 210000003635 pituitary gland Anatomy 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 208000020221 Short stature Diseases 0.000 claims description 4
- JFMKMZZAVDKJAH-QFGZHHBCSA-N (2s)-2-amino-n-[(2r)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 JFMKMZZAVDKJAH-QFGZHHBCSA-N 0.000 claims description 3
- NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 claims description 3
- 108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 claims description 3
- 238000003748 differential diagnosis Methods 0.000 claims description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000028327 secretion Effects 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 37
- 210000002966 serum Anatomy 0.000 abstract description 15
- 239000002676 xenobiotic agent Substances 0.000 abstract description 7
- 230000002034 xenobiotic effect Effects 0.000 abstract description 7
- 125000001151 peptidyl group Chemical group 0.000 abstract description 6
- 102100022831 Somatoliberin Human genes 0.000 description 183
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 106
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 105
- 241000700159 Rattus Species 0.000 description 46
- HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 32
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 31
- 101710202385 Growth hormone secretagogue receptor type 1 Proteins 0.000 description 31
- 229960000208 pralmorelin Drugs 0.000 description 31
- 230000032683 aging Effects 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 239000003488 releasing hormone Substances 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 230000002267 hypothalamic effect Effects 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 230000006735 deficit Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 102000005157 Somatostatin Human genes 0.000 description 9
- 108010056088 Somatostatin Proteins 0.000 description 9
- 229960000553 somatostatin Drugs 0.000 description 9
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 9
- 102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 description 8
- 101710198286 Growth hormone-releasing hormone receptor Proteins 0.000 description 8
- 101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 8
- 230000002238 attenuated effect Effects 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000002405 diagnostic procedure Methods 0.000 description 8
- NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 5
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 238000009256 replacement therapy Methods 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 210000001875 somatotroph Anatomy 0.000 description 5
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 102000002265 Human Growth Hormone Human genes 0.000 description 4
- 108010000521 Human Growth Hormone Proteins 0.000 description 4
- 239000000854 Human Growth Hormone Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000006274 endogenous ligand Substances 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000036119 Frailty Diseases 0.000 description 2
- 102100020948 Growth hormone receptor Human genes 0.000 description 2
- 206010021067 Hypopituitarism Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 2
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 241001164593 Merica Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 2
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- WZHKXNSOCOQYQX-KAGZITNASA-N growth hormone releasing hexapeptide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-KAGZITNASA-N 0.000 description 2
- 239000003324 growth hormone secretagogue Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 229960002290 pyridostigmine Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000025185 skeletal muscle atrophy Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 101710099093 Growth hormone receptor Proteins 0.000 description 1
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 101500023492 Lithobates catesbeianus Growth hormone-releasing peptide Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000008841 allosteric interaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940124642 endogenous agent Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000007166 healthy aging Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004522 neurosecretory neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 1
- 208000003068 pituitary dwarfism Diseases 0.000 description 1
- 230000006584 pituitary dysfunction Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- BVLCEKWPOSAKSZ-YQMCHIOTSA-N sermorelin acetate Chemical compound CC(O)=O.C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 BVLCEKWPOSAKSZ-YQMCHIOTSA-N 0.000 description 1
- 108010056001 somatotropin releasing hormone (1-29) Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/61—Growth hormones [GH] (Somatotropin)
Definitions
- GH growth hormone
- a diagnostic protocol and kit for evaluating pituitary growth hormone (GH) secretory capability as a means to identify the etiology of GH deficiency in children and adults includes measuring GH secretion, as determined by changes in serum, plasma, or whole blood GH concentrations following administration of the xenobiotic GH releasing hexapeptide (GHRP-6) or any of its peptidyl or non-peptidyl synthetic analogues that release GH by the same cellular mechanism as GHRP-6 (the group/family of compounds are referred to as GHRX) .
- GHRP-6 xenobiotic GH releasing hexapeptide
- GHRX group/family of compounds
- FIGURE 1 is a diagram of the three step provocative testing of the present invention.
- FIGURE 2 is a dose response curve for GHRP-6 in rats pretreated with vehicle (triangles) , ⁇ r-methyl-p- tyrosine (circles) , or GHRH antiserum (squares) . Values represent means ⁇ SEM (8 rats per dose and treatment) in plasma collected 15 minutes after administration of GHRP- 6.
- GHRH has been identified as a naturally occurring GH secretagogue, an endogenous analogue of a group referred to as GH releasing compound (GHRC) .
- GHRP-6 represents a synthetic analogue of another, yet unidentified, endogenous GH secretagogue.
- the relationship between GHRP-6 and its endogenous counterpart is presumably analogous to that of morphine and the endorphins.
- GHRP-6 and analogues thereof means GHRP-6 and any peptide or nonpeptide compound that releases GH by the same cellular mechanism.
- analogue Dorland ' s Illustra ted Medical Dictionary, 25th Edition, W.B. Saunders, Philadelphia, PA., p. 78
- analogue in the present invention is used to refer to functional and metabolic analogues that are peptides or nonpeptides that cause the release of GH by the same cellular mechanism as GHRP-6, i.e., they are compounds of similar activity.
- a nonpeptide functional or metabolic analogue of GHRP-6 has been disclosed by Smith et al . (1993) that acts through the same site as GHRP-6.
- the compound, L-692,429 is antagonized by the same agents as is GHRP-6 and interacted with GRF.
- This and related compounds activate the same cellular receptors and second messengers as GHRP- 6 in the course of initiating its relevant action (e.g. growth hormone release) . All of these analogues and compounds of similar activity are useful in practicing the present invention as described herein; however, these peptides and nonpeptides should not be considered as being exhaustive of the GHRP-6 analogue-compounds useful in practicing the present invention.
- GHRH-efficacy has been reported to be reduced 50 to 75% in old rats (Sonntag et al . , 1983) ; therefore, applicants tested the effect of GHRP-6 alone and in combination with GHRH on GH release in old rats. Peak plasma GH concentrations resulting from GHRP-6 administration in old rats were approximately 60% less than in young rats. In contrast, peak plasma GH concentrations were greater in old rats than in young rats administered GHRP-6 and GHRH. Since target organs sometimes become hyperresponsive when tonic and/or phasic stimulation decreases, than one would expect exaggerated responses to provocative exogenous stimuli under experimental conditions.
- GHRP-6 activity was significantly attenuated in young female rats administered GHRH antiserum or ⁇ -methyl-p-tyrosine to reduce endogenous GHRH concentrations.
- GHRH antiserum or ⁇ -methyl-p-tyrosine was significantly attenuated in young female rats administered GHRH antiserum or ⁇ -methyl-p-tyrosine to reduce endogenous GHRH concentrations.
- naturally occurring decrements in endogenous GHRH during aging contributed to the blunted response to GHRP-6 that applicants observed (Walker et al . , 1991) .
- GHRH activity is also dependent upon a yet unidentified endogenous co-secretagogue whose concentrations decline during aging, then applicants' data support the hypothesis that extrinsic pituitary deficits contribute, at least in part, to attenuated GH secretory responses to administered GHRH.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention porte sur un protocole de diagnostic et un matériel d'évaluation des capacités sécrétoires de l'hormone de croissance hypophysaire (GH) en tant que moyen d'identification de l'étiologie des carences en GH chez l'enfant et chez l'adulte. Ledit protocole consiste à mesurer la sécrétion de GH par mesure des variations de la concentration en GH du sérum, du plasma ou du sang entier suite à l'administration de GHPRP-6 (hexapeptide de libération de GH) xénobiotique, ou de l'un de ses analogues de synthèse, du genre peptidyle ou non peptidyle, libérant la GH par le même mécanisme cellulaire que le GHPRP-6. Le composé de libération (GHRC) du GH naturel ou ses analogues sont également administrés à des enfants ou des adultes atteints de troubles liés à une carence en GH, puis la sécrétion de GH est mesurée. Après avoir évalué les effets d'une administration indépendante de secrétagogues du GH sur les variations de la concentration sanguine de GH, on peut mesurer les effets d'une administration conjointe de différents secrétagogues de GH sur la concentration sanguine de GH chez l'enfant et chez l'adulte.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96908837A EP0871392A4 (fr) | 1995-03-17 | 1996-03-14 | Methode de diagnostic de carences en hormone de croissance hypophysaire |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40584295A | 1995-03-17 | 1995-03-17 | |
| US08/405,842 | 1995-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996029002A1 true WO1996029002A1 (fr) | 1996-09-26 |
Family
ID=23605477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/003607 WO1996029002A1 (fr) | 1995-03-17 | 1996-03-14 | Methode de diagnostic de carences en hormone de croissance hypophysaire |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP0871392A4 (fr) |
| WO (1) | WO1996029002A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007093820A1 (fr) | 2006-02-18 | 2007-08-23 | Ardana Bioscience Limited | Méthodes et kits permettant de diagnostiquer une carence en hormone de croissance |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5246920A (en) * | 1992-06-15 | 1993-09-21 | University Of South Florida | Treatment of hyperprolactinemia |
| WO1994000759A1 (fr) * | 1992-06-29 | 1994-01-06 | University Of South Florida | Procedure de diagnostic permettant d'evaluer l'etiologie de l'insuffisance staturale |
-
1996
- 1996-03-14 EP EP96908837A patent/EP0871392A4/fr not_active Withdrawn
- 1996-03-14 WO PCT/US1996/003607 patent/WO1996029002A1/fr not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5246920A (en) * | 1992-06-15 | 1993-09-21 | University Of South Florida | Treatment of hyperprolactinemia |
| WO1994000759A1 (fr) * | 1992-06-29 | 1994-01-06 | University Of South Florida | Procedure de diagnostic permettant d'evaluer l'etiologie de l'insuffisance staturale |
Non-Patent Citations (11)
| Title |
|---|
| BOWERS C Y, ALSTER D K, FRENTZ J M: "THE GROWTH HORMONE-RELEASING ACTIVITY OF A SYNTHETIC HEXAPEPTIDE INNORMAL MEN AND SHORT STATURED CHILDREN AFTER ORAL ADMINISTRATION", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 74, no. 02, 1 January 1992 (1992-01-01), US, pages 292 - 298, XP001052748, ISSN: 0021-972X, DOI: 10.1210/jc.74.2.292 * |
| BOWERS C Y, ET AL.: "GROWTH HORMONE (GH)-RELEASING PEPTIDE STIMULATES GH RELEASE IN NORMAL MEN AND ACTS SYNERGISTICALLY WITH GH-RELEASING HORMONE", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 70, no. 04, 1 January 1990 (1990-01-01), US, pages 975 - 982, XP001052749, ISSN: 0021-972X * |
| BOWERS C. Y., ET AL.: "STRUCTURE-ACTIVITY RELATIONSHIPS OF A SYNTHETIC PENTAPEPTIDE THAT SPECIFICALLY RELEASES GROWTH HORMONE IN VITRO.", ENDOCRINOLOGY, THE ENDOCRINE SOCIETY, US, vol. 106., no. 03., 1 March 1980 (1980-03-01), US, pages 663 - 667., XP000607438, ISSN: 0013-7227 * |
| BUTENANDT O: "DIAGNOSTIC VALUE OF GROWTH HORMONE-RELEASING HORMONE TESTS IN SHORTCHILDREN", ACTA PAEDIATRICA SCANDINAVICA, WILEY, ALMQVIST OCH WIKSELL, STOCKHOLM, SE, vol. 349, 1 January 1989 (1989-01-01), ALMQVIST OCH WIKSELL, STOCKHOLM, SE, pages 93 - 99, XP001052743, ISSN: 0001-656X * |
| CHENG K, ET AL.: "THE SYNERGISTIC EFFECTS OF HIS-D-TRP-ALA-TRP-D-PHE-LYS-NH2 ON GROWTH HORMONE (GH)-RELEASING FACTOR-STIMULATED GH RELEASE AND INTRACELLULAR ADENOSINE 3',5'-MONOPHOSPHATE ACCUMULATION IN RAT PRIMARY PITUITARY CELL CULTURE", ENDOCRINOLOGY, THE ENDOCRINE SOCIETY, US, vol. 124, no. 06, 1 January 1989 (1989-01-01), US, pages 2791 - 2798, XP001052744, ISSN: 0013-7227 * |
| CORDIDO F, ET AL.: "MASSIVE GROWTH HORMONE (GH) DISCHARGE IN OBESE SUBJECTS AFTER THE COMBINED ADMINISTRATION OF GH-RELEASING HORMONE AND GHRP-6: EVIDENCE FOR A MARKED SOMATOTROPH SECRETORY CAPABILITY IN OBESITY", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 76, no. 04, 1 January 1993 (1993-01-01), US, pages 819 - 823, XP001052747, ISSN: 0021-972X, DOI: 10.1210/jc.76.4.819 * |
| GERTZ B J, ET AL.: "GROWTH HORMONE RESPONSE IN MAN TO L-692,429, A NOVEL NONPEPTIDE MIMIC OF GROWTH HORMONE-RELEASING PEPTIDE-6", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 77, no. 05, 1 January 1993 (1993-01-01), US, pages 1393 - 1397, XP001052751, ISSN: 0021-972X, DOI: 10.1210/jc.77.5.1393 * |
| MOMANY F A, ET AL.: "CONFORMATIONAL ENERGY STUDIES AND IN VITRO AND IN VIVO ACTIVITY DATA ON GROWTH HORMONE-RELEASING PEPTIDES", ENDOCRINOLOGY, THE ENDOCRINE SOCIETY, US, vol. 114, no. 05, 1 January 1984 (1984-01-01), US, pages 1531 - 1536, XP001052745, ISSN: 0013-7227 * |
| MOMANY F A, ET AL.: "DESIGN, SYNTHESIS, AND BIOLOGICAL ACTIVITY OF PEPTIDES WHICH RELEASE GROWTH HORMONE IN VITRO", ENDOCRINOLOGY, THE ENDOCRINE SOCIETY, US, vol. 108, no. 01, 1 January 1981 (1981-01-01), US, pages 31 - 39, XP001052746, ISSN: 0013-7227 * |
| ROBINSON B M, ET AL.: "ACUTE GROWTH HORMONE (GH) RESPONSE TO GH-RELEASING HEXAPEPTIDE IN HUMANS IS INDEPENDENT OF ENDOGENOUS GH-RELEASING HORMONE", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 75, no. 04, 1 January 1992 (1992-01-01), US, pages 1121 - 1124, XP001052750, ISSN: 0021-972X, DOI: 10.1210/jc.75.4.1121 * |
| See also references of EP0871392A4 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007093820A1 (fr) | 2006-02-18 | 2007-08-23 | Ardana Bioscience Limited | Méthodes et kits permettant de diagnostiquer une carence en hormone de croissance |
| JP2009526989A (ja) * | 2006-02-18 | 2009-07-23 | アーダナ バイオサイエンス リミテッド | 方法及びキット |
| JP4852728B2 (ja) * | 2006-02-18 | 2012-01-11 | エテルナ ツェンタリス ゲーエムベーハー | 方法及びキット |
| US8192719B2 (en) | 2006-02-18 | 2012-06-05 | Aeterna Zentaris Gmbh | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0871392A4 (fr) | 2001-08-29 |
| EP0871392A1 (fr) | 1998-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Corpas et al. | Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men | |
| Cordido et al. | Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity | |
| Chapman et al. | Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects | |
| Jaffe et al. | Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli. | |
| Nakagawa et al. | Hyperglycaemia suppresses the secretion of ghrelin, a novel growth-hormone-releasing peptide: responses to the intravenous and oral administration of glucose | |
| Mocchegiani et al. | Influence of growth hormone on thymic endocrine activity in humans | |
| Allain et al. | Changes in growth hormone, insulin, insulinlike growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome | |
| Friend et al. | The orderliness of the growth hormone (GH) release process and the mean mass of GH secreted per burst are highly conserved in individual men on successive days | |
| Ghigo et al. | Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature | |
| Thorner et al. | Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group | |
| Veldhuis et al. | Responsiveness of gonadotropin secretion to infusion of an opiate-receptor antagonist in hypogonadotropic individuals | |
| Ranke | Diagnosis of growth hormone deficiency and growth hormone stimulation tests | |
| CHALEW et al. | Growth hormone (GH) response to GH-releasing hormone in children with subnormal integrated concentrations of GH | |
| Robertson et al. | Prolactin response to morphine in depression | |
| US5811074A (en) | Method of diagnosing pituitary dependent growth hormone deficiency | |
| Cordido et al. | Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects | |
| LOCHE et al. | Augmentation of growth hormone secretion in children with constitutional growth delay by short term clonidine administration: a pulse amplitude-modulated phenomenon | |
| Thorner et al. | Neuroendocrine regulation of growth hormone secretion | |
| SHULMAN et al. | Evaluation of Growth Hormone Secretion: Provocative Testing vs Endogenous 24‐hour Growth Hormone Profile | |
| Facchinetti et al. | Neuroendocrine evaluation of central opiate activity in primary headache disorders | |
| Ranke et al. | Testing with growth hormone-releasing factor (GRF (1–29) NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency | |
| WO1996029002A1 (fr) | Methode de diagnostic de carences en hormone de croissance hypophysaire | |
| Martha et al. | Atenolol enhances growth hormone release to exogenous growth hormone-releasing hormone but fails to alter spontaneous nocturnal growth hormone secretion in boys with constitutional delay of growth | |
| EP0650597A1 (fr) | Procedure de diagnostic permettant d'evaluer l'etiologie de l'insuffisance staturale | |
| CA2216260A1 (fr) | Methode pour diagnostiquer la carence en hormone de croissance hypophysaire |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP MX US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1996908837 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1996908837 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1996908837 Country of ref document: EP |